RankingsPricing
  1. US-listed companies
  2. VERTEX PHARMACEUTICALS INC
  3. Financials
  4. Free cash flow

VERTEX PHARMACEUTICALS INCVRTX

Market cap
$109.6B
P/E ratio
SummaryFinancials
Period EndFree cash flow (Million USD)YoY (%)
Dec 31, 2024-790-123.68%
Dec 31, 20233,337-14.99%
Dec 31, 20223,925+62.97%
Dec 31, 20212,409-19.55%
Dec 31, 20202,994+100.40%
Dec 31, 20191,494+27.16%
Dec 31, 20181,175+57.58%
Dec 31, 2017746+315.24%
Dec 31, 2016180-143.71%
Dec 31, 2015-411-27.23%
Dec 31, 2014-564+448.16%
Dec 31, 2013-103-152.34%
Dec 31, 2012197+80.23%
Dec 31, 2011109-116.20%
Dec 31, 2010-673

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)